AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations

Amazon Web Services (AWS)Today, Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ: AMZN), announced a multi-year strategic collaboration with Novartis to reimagine this leading pharmaceutical company's core pharmaceutical manufacturing, supply chain, and delivery operations using AWS's portfolio of cloud services. This enterprise-wide data and analytics platform is expected to form the foundation for custom solutions powered by AWS AI and ML services to help drive agility, innovation, and cost efficiencies across Novartis global business processes and systems.

Core to this collaboration is the creation of Novartis 'Insight Centers' that provide real-time visibility across its network of manufacturing operations and distribution centers. Building on the success of its trial operations center SENSE, these 'Insight Centers' can enable manufacturing and planning teams to better forecast and track production lines, detect potential bottlenecks and then make adjustment recommendations to improve accuracy. Using AWS, Novartis can collect inventory, quality, and production data across its network and apply AWS Internet of Things (IoT), analytics, and machine learning (ML) services to gain greater visibility and help drive efficiencies. By centralizing this data, Novartis data scientists can also experiment with new optimization models to help ramp up the production of innovative, personalized treatments that are more complex to make.

In addition, Novartis plans to use AWS IoT services to augment and improve visual inspections of its manufacturing sites by generating images that can be analyzed using computer vision algorithms to monitor for risks to manufacturing production, such as unplanned downtime or delayed orders. With this real-time data, Novartis associates can be better equipped to make data-based decisions that help ensure medicines are efficiently produced and distributed to nearly 1 billion patients in 155 countries around the world.

"I'm really proud of how the teams are working together on the ground to bring Amazon-like user experiences to our associates. There is a lot we can learn from the AWS team, and while manufacturing is a great starting place, we're keen to also explore where else we can apply this technology," said Bertrand Bodson, Chief Digital Officer at Novartis. "Using data science and digital technologies to reimagine the way we manufacture medicines is not only at the heart of our transformation, but also core to our ambition to bring innovative medicines to patients faster."

"We are excited about this collaboration, bringing together AWS's unmatched portfolio of services with deep Novartis expertise in the way they manufacture pharmaceuticals and the way they approach supply chain processes," said Mike Clayville, Vice President, Worldwide Commercial Sales at AWS. "AWS's security, scalability, and highly reliable infrastructure can help Novartis advance its technical operations with greater agility and customer-orientation, and potentially reducing the time it takes to bring innovative medicines to patients."

About Amazon Web Services

For 13 years, Amazon Web Services has been the world's most comprehensive and broadly adopted cloud platform. AWS offers over 175 fully featured services for compute, storage, databases, networking, analytics, robotics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 69 Availability Zones (AZs) within 22 geographic regions, with announced plans for 13 more Availability Zones and four more AWS Regions in Indonesia, Italy, South Africa, and Spain. Millions of customers - including the fastest-growing startups, largest enterprises, and leading government agencies - trust AWS to power their infrastructure, become more agile, and lower costs.

About Amazon

Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon.

Most Popular Now

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...

Sanofi and Translate Bio mRNA COVID-19 vaccine can…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced...